NPPA and Huntington disease: Furthermore, the absence of a strong relationship between the level of any of the KP metabolites in either CSF or plasma with HD clinical measures or disease burden based on CAG length suggests that KP metabolite levels cannot be used as pharmacodynamic biomarkers either during therapeutic intervention or disease progression.